Published in Eur J Immunol on February 01, 2000
Infection and activation of monocytes by Marburg and Ebola viruses. J Virol (2001) 1.90
Caspase-1 dependent IL-1β secretion is critical for host defense in a mouse model of Chlamydia pneumoniae lung infection. PLoS One (2011) 1.25
Induction of proinflammatory cytokines in human lung epithelial cells during Chlamydia pneumoniae infection. Infect Immun (2003) 0.96
Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. Antimicrob Agents Chemother (2002) 0.92
Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview. Int J Mol Sci (2013) 0.88
Ectasia and severe atherosclerosis: relationships with chlamydia pneumoniae, helicobacterpylori, and inflammatory markers. Tex Heart Inst J (2005) 0.86
Chlamydia pneumoniae and osteoporosis-associated bone loss: a new risk factor? Osteoporos Int (2012) 0.84
Synergistic Costimulatory Effect of Chlamydia pneumoniae with Carbon Nanoparticles on NLRP3 Inflammasome-Mediated Interleukin-1β Secretion in Macrophages. Infect Immun (2015) 0.81
Shear Stress Enhances Chemokine Secretion from Chlamydia pneumoniae-infected Monocytes. Cell Mol Bioeng (2013) 0.80
Biophysical regulation of Chlamydia pneumoniae-infected monocyte recruitment to atherosclerotic foci. Sci Rep (2016) 0.79
Amalgamation of Chlamydia pneumoniae inclusions with lipid droplets in foam cells in human atherosclerotic plaque. Virchows Arch (2008) 0.79
Hydrodynamic regulation of monocyte inflammatory response to an intracellular pathogen. PLoS One (2011) 0.79
Human blood monocytes support persistence, but not replication of the intracellular pathogen C. pneumoniae. BMC Immunol (2014) 0.79
Infection with Chlamydia pneumoniae as a cause of coronary heart disease: the hypothesis is still untested. Pathog Dis (2014) 0.78
Association of plasma circulatory markers, Chlamydia pneumoniae, and high sensitive C-reactive protein in coronary artery disease patients of India. Mediators Inflamm (2009) 0.76
In situ detection of Chlamydia pneumoniae, C. trachomatis, and cytokines among cardiovascular diseased patients from the Amazon region of Brazil. Infect Drug Resist (2017) 0.75
Impact of seropositivity to Chlamydia pneumoniae and anti-hHSP60 on cardiovascular events in hemodialysis patients. Cell Stress Chaperones (2010) 0.75
Biophysical and Biochemical Outcomes of Chlamydia pneumoniae Infection Promotes Pro-atherogenic Matrix Microenvironment. Front Microbiol (2016) 0.75
A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med (2005) 17.06
Interleukin-1. Rev Infect Dis (1984) 11.24
Induction by IL 1 and interferon-gamma: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol (1986) 10.92
Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1. J Exp Med (1986) 10.91
Nucleotide sequence of human monocyte interleukin 1 precursor cDNA. Proc Natl Acad Sci U S A (1984) 8.84
Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med (1988) 7.96
Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science (1987) 7.22
Growth of a cloned helper T cell line induced by a monoclonal antibody specific for the antigen receptor: interleukin 1 is required for the expression of receptors for interleukin 2. J Immunol (1984) 5.51
Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest (1988) 5.22
Interleukin-1 and the pathogenesis of the acute-phase response. N Engl J Med (1984) 5.12
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect (2012) 4.56
Dimensional assessment of chronic fatigue syndrome. J Psychosom Res (1994) 4.35
Porphyromonas gingivalis invasion of gingival epithelial cells. Infect Immun (1995) 4.33
Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones. Science (1986) 4.25
General primer-mediated polymerase chain reaction for detection of enteroviruses: application for diagnostic routine and persistent infections. J Clin Microbiol (1992) 4.18
Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood (1994) 3.74
Interleukin 1 induces interleukin 1. I. Induction of circulating interleukin 1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol (1987) 3.61
Interleukin-18 (IFNgamma-inducing factor) induces IL-8 and IL-1beta via TNFalpha production from non-CD14+ human blood mononuclear cells. J Clin Invest (1998) 3.54
Stimulation of muscle protein degradation and prostaglandin E2 release by leukocytic pyrogen (interleukin-1). A mechanism for the increased degradation of muscle proteins during fever. N Engl J Med (1983) 3.49
Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response. Immunity (1999) 3.43
Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest (1986) 3.43
Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol (1986) 3.35
[Anthrax due to deliberate infection]. Ned Tijdschr Geneeskd (2001) 3.33
Ability of human leukocytic pyrogen to enhance phytohemagglutinin induced murine thymocyte proliferation. Cell Immunol (1981) 3.22
IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci U S A (2001) 3.21
Human leukocytic pyrogen: purification and development of a radioimmunoassay. Proc Natl Acad Sci U S A (1977) 3.15
Inflammatory markers and the risk of Alzheimer disease: the Framingham Study. Neurology (2007) 3.12
Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression. J Clin Invest (1986) 3.05
Genus- and species-specific identification of mycoplasmas by 16S rRNA amplification. Appl Environ Microbiol (1992) 3.05
Demonstration and characterization of two distinct human leukocytic pyrogens. J Exp Med (1974) 2.98
[Choice of antibiotics in uncomplicated cystitis; application of 'system of objectified judgement analysis' (SOJA) method]. Ned Tijdschr Geneeskd (1999) 2.97
An update on human interleukin-1: from molecular biology to clinical relevance. J Clin Immunol (1985) 2.90
Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science (1988) 2.87
Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest (1990) 2.86
Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med (1985) 2.84
Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest (2001) 2.84
Cytotoxicity of human pI 7 interleukin-1 for pancreatic islets of Langerhans. Science (1986) 2.83
Interleukin 1 stimulates fibroblasts to produce granulocyte-macrophage colony-stimulating activity and prostaglandin E2. J Clin Invest (1986) 2.82
Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1). J Clin Immunol (1999) 2.79
Lymphokines. N Engl J Med (1987) 2.77
Isolation of an interleukin-1-like factor from human joint effusions. Arthritis Rheum (1983) 2.75
Molecular basis of fever in humans. Am J Med (1982) 2.69
Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate. J Immunol (1986) 2.68
Adherent cell function in murine T-lymphocyte antigen recognition. IV. Enhancement of murine T-cell antigen recognition by human leukocytic pyrogen. J Exp Med (1979) 2.64
Tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med (1999) 2.63
Gene expression, synthesis, and secretion of interleukin 18 and interleukin 1beta are differentially regulated in human blood mononuclear cells and mouse spleen cells. Proc Natl Acad Sci U S A (1999) 2.57
Inducible expression of human beta-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect Immun (2000) 2.55
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
[New developments in antifungal therapy: fluconazole, itraconazole, voriconazole, caspofungin]. Ned Tijdschr Geneeskd (2004) 2.55
A specific receptor antagonist for interleukin 1 prevents Escherichia coli-induced shock in rabbits. FASEB J (1991) 2.52
Human leukocytic pyrogen induces release of specific granule contents from human neutrophils. J Clin Invest (1978) 2.48
IL-1 induction-capacity of defined lipopolysaccharide partial structures. J Immunol (1989) 2.41
Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. J Immunol (2001) 2.41
Tumour necrosis factor production in Falciparum malaria and its association with schizont rupture. Clin Exp Immunol (1989) 2.41
IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 2.37
Enhancement of growth of virulent strains of Escherichia coli by interleukin-1. Science (1991) 2.37
Colchicine therapy for familial mediterranean fever. A double-blind trial. N Engl J Med (1974) 2.35
Chemotactic cytokines: the role of leukocytic pyrogen and epidermal cell thymocyte-activating factor in neutrophil chemotaxis. J Immunol (1984) 2.34
Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome. J Clin Invest (1984) 2.33
Acute inflammation and a Shwartzman-like reaction induced by interleukin-1 and tumor necrosis factor. Synergistic action of the cytokines in the induction of inflammation and microvascular injury. Am J Pathol (1987) 2.27
Atypical herpes simplex virus encephalitis diagnosed by PCR amplification of viral DNA from CSF. Neurology (1998) 2.26
Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis (2008) 2.25
A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci U S A (1988) 2.22
Interleukin-1 immunoreactive innervation of the human hypothalamus. Science (1988) 2.22
Inducible interleukin-1 gene expression in human vascular smooth muscle cells. J Clin Invest (1986) 2.21
Role of arachidonate metabolism in the immunoregulatory function of human leukocytic pyrogen/lymphocyte-activating factor/interleukin 1. J Immunol (1983) 2.20
The challenge of Lyme disease: tired of the Lyme wars. Neth J Med (2011) 2.20
Staphylococcus epidermidis induces complement activation, tumor necrosis factor and interleukin-1, a shock-like state and tissue injury in rabbits without endotoxemia. Comparison to Escherichia coli. J Clin Invest (1991) 2.17
Multiple biological activities of human recombinant interleukin 1. J Clin Invest (1986) 2.16
Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol (2001) 2.16
Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol (1991) 2.15
Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A (2000) 2.14
The events of primary T cell activation can be staged by use of Sepharose-bound anti-T3 (64.1) monoclonal antibody and purified interleukin 1. J Immunol (1985) 2.14
Response to local inflammation of IL-1 beta-converting enzyme- deficient mice. J Immunol (1997) 2.10
The measurement of fatigue in patients with multiple sclerosis. A multidimensional comparison with patients with chronic fatigue syndrome and healthy subjects. Arch Neurol (1996) 2.09
Coxsackievirus protein 2B modifies endoplasmic reticulum membrane and plasma membrane permeability and facilitates virus release. EMBO J (1997) 2.09
The IL-1 receptor/toll-like receptor superfamily: crucial receptors for inflammation and host defense. Immunol Today (2000) 2.09
Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet (2001) 2.08
Balance of synovial fluid IL-1 beta and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet (1993) 2.05
The effects of interleukin 1 on human B cell activation and proliferation. J Immunol (1983) 2.05
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons. Cancer Res (1998) 2.04
Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18. Proc Natl Acad Sci U S A (2000) 2.03
Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections. J Clin Invest (1996) 2.03
Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest (1994) 2.01
[Chronic fatigue syndrome. I. Somatological hypothesis]. Ned Tijdschr Geneeskd (1991) 2.01
Study on microbial persistence in end-stage idiopathic dilated cardiomyopathy. Clin Infect Dis (1999) 2.01
Endurance run increases circulating IL-6 and IL-1ra but downregulates ex vivo TNF-alpha and IL-1 beta production. J Appl Physiol (1985) (1995) 1.99
Ability of human leukocytic pyrogen to stimulate brain prostaglandin synthesis in vitro. J Neurochem (1981) 1.99
Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery (1988) 1.98
[Belt and suspenders. Medical jargon in The Netherlands and Flanders]. Ned Tijdschr Geneeskd (1994) 1.97
Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A (2001) 1.97
Increasing levels of interleukin (IL)-1Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation (1999) 1.94
Measurement of immunoreactive interleukin-1 beta from human mononuclear cells: optimization of recovery, intrasubject consistency, and comparison with interleukin-1 alpha and tumor necrosis factor. Clin Immunol Immunopathol (1988) 1.93
The future of scattered trees in agricultural landscapes. Conserv Biol (2008) 1.92
Effect of endotoxin in IL-1 beta-deficient mice. J Immunol (1996) 1.92